Compared to conventional HCC, mutations in CTNNB1, TP53, and TERT promoter are less frequent; however, the interleukin-6 (IL-6)–JAK–STAT signaling pathway is more frequently activated [93,94]. The gene discussed is IL6; the disease is hepatocellular carcinoma.